This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): DU 127090
Description: Bifeprunox differs from most other atypical antipsychotics in that it acts as a partial D2 agonist (like Abilify). In contrast to D2 receptor antagonism, partial D2 agonism is believed to decrease dopamine activity in an overactive dopamine system while simultaneously increasing dopamine activity in regions of the brain where dopaminergic activity is too low. By blocking overstimulated receptors and stimulating underactive ones, partial D2 agonists act as dopamine stabilizers. Bifeprunox also acts as a serotonin, 5-HT1A partial agonist.
Bifeprunox also has high affinity for D3 and D4 receptors, but virtually no affinity for 5-HT2A and 5-HT2C, noradrenergic a1 and a2, muscarinic and histaminergic receptors.
Deal Structure: In December 2000, Lundbeck A/S and Solvay Pharmaceuticals announced that they would join forces in the development and marketing of bifeprunox.
On April 1, 2004, Solvay and Wyeth Pharmaceuticals announced a development and marketing agreement for bifeprunox in the USA, Mexico, Japan and Canada. Lundbeck has marketing rights to bifeprunox in Europe and a number of other markets. Lundbeck and Solvay will jointly market the product in Brazil and Argentina.
In February 2008, Wyeth Pharmaceuticals announced the end of its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox, as well as SLV 313 and SLV314. All development and commercialization rights in North America for bifeprunox as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.
In September 2009, Solvay announced that its Board of Directors has decided to sell its entire pharmaceutical business to Abbott for a total Entreprise Value...See full deal structure in Biomedtracker
Partners: H. Lundbeck A/S
Pink Sheet Wyeth bags bifeprunox
Pink Sheet Wyeth Plans Three NDA Filings By April
Additional information available to subscribers only: